Middleton, Mark R. http://orcid.org/0000-0003-0167-1685
Hoeller, Christoph
Michielin, Olivier
Robert, Caroline
Caramella, Caroline
Öhrling, Katarina
Hauschild, Axel
Funding for this research was provided by:
Medical writing support was funded by Amgen (Europe) GmbH.
Article History
Received: 17 March 2020
Revised: 11 June 2020
Accepted: 29 June 2020
First Online: 27 July 2020
Ethical approval and consent to participate
: This review article does not report new data from any studies with human participants or animals performed by any of the authors.
: Not applicable.
: Not applicable (no datasets were generated or analysed during article).
: M.R.M. has acted as an advisor for Alkermes, Amgen, Astellas (was OSI), Bioline, Boehringer Ingelheim, Bristol-Myers Squibb, Codiak, CytomX, Eisai, GSK, Kineta, Merck, Novartis, Roche, Silicon Therapeutics and Valo Therapeutics; has received grants from AstraZeneca, GSK and Roche; and has received other types of support from Immunocore, Pfizer, Regeneron, Replimune, TC Biopharma, and Vertex. C.H. has acted as a speaker or advisor for Amgen, Bristol-Myers Squibb, Incyte, Merck Sharp & Dohme, Novartis, Pierre Fabre and Roche. O.M. has received honoraria for advisory roles from Amgen, Bristol-Myers Squibb, Novartis and Roche, and research funding from MSD. Caroline Robert has participated in advisory boards for Amgen, Biothera, Bristol-Myers Squibb, Merck Sharp & Dohme, Novartis and Roche. C.C. has received honoraria for advisory roles from Amgen, AstraZeneca, Bristol-Myers Squibb and Roche. K.Ö. is an employee of Amgen (Europe) GmbH and is a stockholder in Amgen. A.H. has received grants and honoraria from Amgen, Bristol-Myers Squibb, Merck Serono, Merck Sharp & Dohme, Philogen, Pierre Fabre, Provectus, Regeneron and Roche, and has received honoraria from OncoSec.
: Medical writing support was funded by Amgen (Europe) GmbH.